(Q46076995)

19 December 2017

title

Insulin detemir in routine clinical practice: a 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE Cohort (English)

1 reference

19 December 2017

1 reference

1 reference

V Preumont

1

1 reference

19 December 2017

M Buysschaert

series ordinal

2

1 reference

19 December 2017

S De Beukelaer

series ordinal

3

1 reference

19 December 2017

C Mathieu

series ordinal

4

1 reference

19 December 2017

publication date

1 January 2009

1 reference

19 December 2017

published in

Acta Clinica Belgica

1 reference

19 December 2017

volume

64

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

49-55

1 reference

19 December 2017

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

cites work

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2009.009

21 January 2018

Identifiers

DOI

10.1179/ACB.2009.009

1 reference

19 December 2017

1 reference

19 December 2017